Auph short interest.

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price.AUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet;Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ...It seems like the purpose of the document is to formalize the recent changes to the commercial partnership (originally announced here) as well as some of the items from the cooperation agreement released in February; particularly when it comes to the availability of stock warrants that Healios can execute once they achieve approvals for ARDS ...

AUPH short interest is 8.5%. Also see, Alnylam Pharma is said to be a potential target for Novartis. Recommended For You. Comments (34) Newest. Publish. Have a tip? Submit confidentially to our ...

Short interest is the volume of Aurinia Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders …... short-term outlook for biotechnology or pharmaceuticals companies.” The top ... interest in any company mentioned in this article. Keep reading...Show less.

Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ...AuriniaPharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 12,670,00WebAUPH. Buyout / ShortSquueze. This jumped from $22 to $28 at 3:54 pm Friday on rumor of BMY buying them out. No news over the weekend . The short interest is 17 percent. Thinking even without a confirmed buyout, shorts may be stuck. Good luck if you trade it.Jul 15, 2022 · Biogen has more recently been seen as a potential acquirer of AUPH after a Stat News report said that Biogen is working with Goldman Sachs to find potential targets for the company. Aurinia ( AUPH ... Aurinia Pharmaceuticals Inc AUPH shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the company announced that its ...Web

The mean of analysts' price targets for Aurinia (AUPH) points to a 59.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...Web

Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) d

AUPH has a market cap of $1.08bn and $400 million of cash, cash equivalents, restricted cash and investments as of October 31, 2022. In the previous quarter, the company made $55mn in revenue ...Short interest is the volume of POINT Biopharma Global shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,390,000 shares of PNT short. 5.09% of POINT Biopharma Global's shares are currently sold short. Learn More on POINT Biopharma Global's current short interest.Are you also wondering what is the USD to VND exchange rate today? Or, how to do US Dollar to Vietnamese Dong conversion? USD to VND exchange rate Nov, 2023 and US Dollar to Vietnamese Dong conversion data by Finance Ai provides historical chart price for US Dollar to Vietnamese Dong with easy to use tools like USD to VND converter to help …WebThe short story “Checkouts” by children and teen author Cynthia Rylant is about the games people play with each other and with themselves when they are interested in someone and do not know how to show it.586. -18.84. 2023-11-22. NP. PSGIX - Blackrock Advantage Small Cap Growth Fund Institutional This fund is a listed as child fund of BlackRock Inc. and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value.In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 16,710,000 shares, a growth of 6.8% from the June 30th total of 15,650,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the […]Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...These cookies may be set through our site by us and our advertising partners to make advertising messages more relevant to you. They perform functions like preventing the same ad from continuously reappearing, ensuring that ads are properly displayed for advertisers, selecting advertisements that are based on your interests and measuring the number of …TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comThe Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...

Author: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…

Artal Group S.A. increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) by 33.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the company’s stock after buying an additional 500,000 …WebZhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) plunged 14% after the company announced Thursday three new executive hires, including a new R&D chief, likely cooling speculation that the company may be acquired.Aurinia also disclosed that its chief commercial officer will be leaving next …Today's Open Interest: The total open interest for all option contracts (across all expiration dates). Open Int (30-Day) : The average total open interest for all option contracts …Mar 24, 2023 · Aurinia's Q4, 2022 earnings call, (the "Call"), delivered on 02/28/2023, provides a report on how Aurinia is doing a full two years on. During the Call CEO Greenleaf advised that Aurinia was ... The SPDR S&P Biotech ETF, one of the largest U.S. biotech ETFs, has a short interest percent of float of 57.7%, according to data from S3 Partners.Mar 2, 2022 · Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ... Affimed saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,640,000 shares, a decline of 24.1% from the October 31st total of 2,160,000 shares. Based on an average daily volume of 562,700 shares, the short-interest ratio is currently 2.9 days. View Affimed's Short Interest.AUPH Short Interest SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER 02/12/2021 5,442,521 4,199,973 1.295847. Reply Like. Delmar Price. 26 Feb. 2021. Investing Group.

Short Interest : 17.19M: Short Previous Month : 17.28M: Short % of Shares Out : 11.97%: Short % of Float : 12.21%: Short Ratio (days to cover) 11.64

Short Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%

Dec 2, 2021 · Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). Novartis reportedly said during its R&D day earlier... Nov 29, 2023 · Short Interest. Percentage of Shares Shorted 11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short. Short Interest Ratio / Days to Cover Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 9.2. Change versus previous month Thinking about investing in Aurinia Pharmaceuticals because of the upcoming earnings date annual report or stock price forecast? Check out AUPH short interest and earnings date annual report by comparing AUPH insider trading history and institutional ownership breakdown to maximise your investment return on the stock market.Aug 24, 2022 · Approximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ... Aug 2, 2023 · Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus... Apr 24, 2023 · MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ... Aurinia Pharmaceuticals AUPH closed the last trading session at $9.04, gaining 22.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.21 indicates a 46.1% upside potential. The average comprises seven short-term …Aurora Cannabis Inc. ACB-T. 10.7%. $29.6. 10.6%. On the 20 most shorted companies by percentage of float table, Canada Goose Holdings Inc. ( GOOS-T) is once again perched at the top, with 32.6 per ...WebAurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...Mission Statement. The mission of ShortSqueeze® is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track short interest in stocks, and gain from the advantages of this powerful market data. Tuesday November 28, 2023. 20 Min Delayed.

Institutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQAurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …Instagram:https://instagram. hyundia stocklithium recycle stockreal estate crowdfunding.how good is fisher investments Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Short Squeeze Ranking™. view. Daily Short Sale Volume. view. Short Interest (Shares Short) unit dividenddividend calendar for stocks The largest shareholder of Aurinia Pharmaceuticals (NASDAQ:AUPH) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% ...Aurinia Pharmaceuticals (AUPH) Short Interest Ratio & Short Volume $8.85 -0.39 (-4.22%) (As of 03:22 PM ET) Compare Today's Range $8.77 $10.05 50-Day Range $7.13 $9.24 52-Week Range $4.07 $12.43 Volume 6.25 million shs Average Volume 2.60 million shs Market Capitalization $1.27 billion P/E Ratio N/A Dividend Yield N/A Price Target $14.00 globant sa Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin ...Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ...In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...